Bioventus (NASDAQ:BVS) Shares Down 6.8% – What’s Next?
by Amy Steele · The Cerbat GemBioventus Inc. (NASDAQ:BVS – Get Free Report)’s stock price fell 6.8% during trading on Wednesday . The stock traded as low as $8.60 and last traded at $8.4050. 334,402 shares traded hands during trading, a decline of 17% from the average session volume of 403,737 shares. The stock had previously closed at $9.02.
Analyst Ratings Changes
Several research firms recently commented on BVS. Barrington Research reissued an “outperform” rating and set a $14.00 price objective on shares of Bioventus in a research note on Friday, May 22nd. CJS Securities began coverage on shares of Bioventus in a research note on Friday, March 27th. They set a “market outperform” rating and a $14.00 price objective on the stock. Cantor Fitzgerald raised shares of Bioventus to a “strong-buy” rating in a research note on Wednesday, March 4th. Finally, Craig Hallum boosted their price objective on shares of Bioventus from $15.00 to $16.00 and gave the stock a “buy” rating in a research note on Friday, March 6th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $14.00.
Get Our Latest Analysis on Bioventus
Bioventus Price Performance
The company has a quick ratio of 1.13, a current ratio of 1.69 and a debt-to-equity ratio of 1.08. The firm has a market capitalization of $746.85 million, a PE ratio of 21.80, a PEG ratio of 1.18 and a beta of 0.72. The firm’s fifty day simple moving average is $9.68 and its 200-day simple moving average is $8.51.
Bioventus (NASDAQ:BVS – Get Free Report) last issued its earnings results on Wednesday, May 6th. The company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.09 by $0.06. The business had revenue of $132.09 million during the quarter. Bioventus had a net margin of 4.94% and a return on equity of 29.97%. Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. On average, research analysts forecast that Bioventus Inc. will post 0.79 earnings per share for the current fiscal year.
Insider Transactions at Bioventus
In other Bioventus news, Director Michelle Mcmurry-Heath sold 12,000 shares of Bioventus stock in a transaction dated Wednesday, March 11th. The shares were sold at an average price of $8.79, for a total value of $105,480.00. Following the completion of the transaction, the director directly owned 44,997 shares of the company’s stock, valued at approximately $395,523.63. The trade was a 21.05% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 33.00% of the company’s stock.
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of the company. Marshall Wace LLP raised its holdings in Bioventus by 0.4% in the fourth quarter. Marshall Wace LLP now owns 288,900 shares of the company’s stock worth $2,149,000 after buying an additional 1,281 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Bioventus by 7.2% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,048 shares of the company’s stock valued at $211,000 after purchasing an additional 1,538 shares during the last quarter. Mercer Global Advisors Inc. ADV raised its holdings in shares of Bioventus by 16.2% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 13,529 shares of the company’s stock valued at $101,000 after purchasing an additional 1,887 shares during the last quarter. Deutsche Bank AG raised its holdings in shares of Bioventus by 8.2% during the fourth quarter. Deutsche Bank AG now owns 25,138 shares of the company’s stock valued at $187,000 after purchasing an additional 1,908 shares during the last quarter. Finally, Covestor Ltd raised its holdings in shares of Bioventus by 28.0% during the third quarter. Covestor Ltd now owns 9,951 shares of the company’s stock valued at $67,000 after purchasing an additional 2,176 shares during the last quarter. 62.94% of the stock is owned by hedge funds and other institutional investors.
Bioventus Company Profile
Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.